| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 8.6 | 11.3 |
| Gross profit | 6.6 | 8.7 |
| Profit before tax | -1.4 | 9.7 |
| Net income | -1.4 | 9.7 |
| EPS (diluted, $ a share) | $-0.16 | $0.39 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -23.9% |
|---|---|
| Gross margin | 77.3% |
| Operating margin | -12.5% |
10-Q filed with the SEC, NASDAQ: SNWV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sanuwave Health, Inc.: key numbers
- Share price
- $1.81Close, Nov 16
- Market cap
- $15.6M
- Shares outstanding
- 8.6MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sanuwave Health, Inc.
All →Sanuwave Health Financial Results
SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.
- Term
- Q3 2026
“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”
Morgan Frank, CEO
Sanuwave Health Debt Financing Update with JPMorgan Chase Bank, N.A.
SANUWAVE Health entered into an amendment and waiver to its existing credit agreement with JPMorgan Chase Bank. The lenders waived a default related to the fixed charge coverage ratio for the period ending September 30, 2026, while tightening restrictions on acquisitions, stock repurchases, and permitted indebtedness.
- Counterparty
- JPMorgan Chase Bank, N.A.
Sanuwave Health Nasdaq/NYSE Compliance Notice
SANUWAVE Health received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, or until March 22, 2027, to regain compliance by maintaining an MVLS of at least $50 million for 10 consecutive business days.
- Counterparty
- Nasdaq
- Term
- 180 days